CombiMatrix - Strategische Neuausrichtung auf Prenatal-Tests mit CMA (chromosomal microarray analysi - 500 Beiträge pro Seite
eröffnet am 28.02.13 15:15:33 von
neuester Beitrag 16.10.14 19:33:03 von
neuester Beitrag 16.10.14 19:33:03 von
Beiträge: 51
ID: 1.179.766
ID: 1.179.766
Aufrufe heute: 0
Gesamt: 4.453
Gesamt: 4.453
Aktive User: 0
ISIN: US20009T5011 · WKN: A2AD52
5,2870
EUR
+0,95 %
+0,0500 EUR
Letzter Kurs 15.11.17 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 0,9300 | +54,46 | |
| 0,5055 | +41,91 | |
| 6,8200 | +36,95 | |
| 2,4700 | +33,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,4400 | -17,70 | |
| 5,0550 | -22,71 | |
| 6,0500 | -22,93 | |
| 0,9000 | -23,08 | |
| 1,2250 | -38,44 |
Feedback
CombiMatrix Management Discusses Q4 2012 Results
Zitat Mark McDonough (neuer CEO ab 15.03.2013)
"[....]
Today, we are focused on where the market is growing and leveraging what distinguishes CombiMatrix in the marketplace, prenatal and pediatric testing, particularly , chromosomal microarray analysis, which we call CMA.
We are the only publicly-traded company in the world today that specializes in CMA.
[...]"
Angesichts der gestiegenen Einnahmen und der gebremsten Cash Burn Rate ist neue Hoffnung in der Aktie. Technologisch sind die Weichen gut gestellt, das Pferd reitet in die richtige Richtung, die Frage ist, ob der Gaul durchhält.
Die gewaltigen Pegelausschläge im Aktienkurs reizen zum Einstieg, wenn die Firma durchhält locken einzigartige Gewinnchancen.
Andererseits fällt der Kurs ohne positive Nachrichten schnell ab und geht in einen rasanten Sinkflug über (wie aktuell zu beobachten).
Diese Aktie ist definitiv nur was für starke Nerven.
Zitat Mark McDonough (neuer CEO ab 15.03.2013)
"[....]
Today, we are focused on where the market is growing and leveraging what distinguishes CombiMatrix in the marketplace, prenatal and pediatric testing, particularly , chromosomal microarray analysis, which we call CMA.
We are the only publicly-traded company in the world today that specializes in CMA.
[...]"
Angesichts der gestiegenen Einnahmen und der gebremsten Cash Burn Rate ist neue Hoffnung in der Aktie. Technologisch sind die Weichen gut gestellt, das Pferd reitet in die richtige Richtung, die Frage ist, ob der Gaul durchhält.
Die gewaltigen Pegelausschläge im Aktienkurs reizen zum Einstieg, wenn die Firma durchhält locken einzigartige Gewinnchancen.
Andererseits fällt der Kurs ohne positive Nachrichten schnell ab und geht in einen rasanten Sinkflug über (wie aktuell zu beobachten).
Diese Aktie ist definitiv nur was für starke Nerven.
Und noch ein Schlüsselzitat aus dem Bericht:
"[...]
strategy of focusing on the prenatal markets and on the CMAs, those are the highest reimbursed tests that we perform. They carry the best gross margin of any of our tests, and that's where all of the growth is coming right now. So we're excited about maximizing that opportunity and
I think in the relative short term, turning around that breakeven point relatively quickly. [...]"
Scott R. Burell (CCO Chief Commercial Officer)
Das klingt mal ziemlich vielversprechend. Wenn das stimmt, könnte der nächste Quartalsbericht wieder einen Raketenstart auslösen.
Wie schnell das beim leisesten Optimismusschimmer geht, haben wir ja in den letzten Wochen und Monaten ja mehrmals staunend miterleben dürfen (wenn auch von der Seitenlinie aus).
"[...]
strategy of focusing on the prenatal markets and on the CMAs, those are the highest reimbursed tests that we perform. They carry the best gross margin of any of our tests, and that's where all of the growth is coming right now. So we're excited about maximizing that opportunity and
I think in the relative short term, turning around that breakeven point relatively quickly. [...]"
Scott R. Burell (CCO Chief Commercial Officer)
Das klingt mal ziemlich vielversprechend. Wenn das stimmt, könnte der nächste Quartalsbericht wieder einen Raketenstart auslösen.
Wie schnell das beim leisesten Optimismusschimmer geht, haben wir ja in den letzten Wochen und Monaten ja mehrmals staunend miterleben dürfen (wenn auch von der Seitenlinie aus).
Jetzt steigts wieder leicht, ist das der Boden?
Nach den positiven Nachrichten dürfte es eigentlich nicht mehr so rasant nach unten weitergehen.
Nach den positiven Nachrichten dürfte es eigentlich nicht mehr so rasant nach unten weitergehen.
haben genau noch für 1 Quartal Cash
so der superpick ist das nicht
so der superpick ist das nicht
Antwort auf Beitrag Nr.: 44.204.699 von niumpica am 01.03.13 18:48:44
Auszug:
[...] is if you take the cash on hand and you do the burn rate, just some qick math in my head says we could be running out of cash by late summer. What are your thouhgts on that?
R. Judd Jessup:
Yes, that's a good question. We're doing a number of things. As you might have seen yesterday, we modified the warrants under our Series A financing so that they can be exercised now. And these warrants are currently in the money and could generate as much as $1.7 million in near-term capital, assuming they were all exercised. In addition, we're considering other financial opportunities in term of capital raising, and we're fairly far down the road with those. So I guess, in short, I would say that I'm optimistic that we will be able to raise additional money in both of these ways and don't see a problem there. "
Auszug:
[...] is if you take the cash on hand and you do the burn rate, just some qick math in my head says we could be running out of cash by late summer. What are your thouhgts on that?
R. Judd Jessup:
Yes, that's a good question. We're doing a number of things. As you might have seen yesterday, we modified the warrants under our Series A financing so that they can be exercised now. And these warrants are currently in the money and could generate as much as $1.7 million in near-term capital, assuming they were all exercised. In addition, we're considering other financial opportunities in term of capital raising, and we're fairly far down the road with those. So I guess, in short, I would say that I'm optimistic that we will be able to raise additional money in both of these ways and don't see a problem there. "
Trading Spotlight
Scheinen doch recht entspannt zu sein, die CEO und COO's von CombiMatrix wenns um die Zukunft geht. Haben da wohl noch einige Investoren im Hintergrund für ihre Optionsscheine.
Hauptsache der Laden steigert seinen Umsatz weiterhin mit der jüngst erreichten Zuwachsrate im profitableren CMA-Geschäft. Dann dürfte der Cash Burn bald der Vergangenheit angehören.
Hauptsache der Laden steigert seinen Umsatz weiterhin mit der jüngst erreichten Zuwachsrate im profitableren CMA-Geschäft. Dann dürfte der Cash Burn bald der Vergangenheit angehören.
11.03.2013: ca. 14.30 Uhr: leichter Kursanstieg
11.03.2013: ca. 15.00 Uhr: Raketenstart 30% (Nasdaq)
11.03.2013: ca. 16.00 Uhr: 36% (Nasdaq)
Was für eine Achterbahnfahrt!
Gott sei Dank bin ich bei 2,27 EUR eingestiegen. Der Verlust vom letzten "Notausstieg" wäre jetzt wieder im Kasten. Mannomann. Das hätte mein Ego auch nicht verkraftet, Geld zu verlieren an der Börse, und das als Aurakel. Was war das für ein ungewohntes, hässliches Gefühl. Aber jetzt ist es geheilt. :-)
11.03.2013: ca. 15.00 Uhr: Raketenstart 30% (Nasdaq)
11.03.2013: ca. 16.00 Uhr: 36% (Nasdaq)
Was für eine Achterbahnfahrt!
Gott sei Dank bin ich bei 2,27 EUR eingestiegen. Der Verlust vom letzten "Notausstieg" wäre jetzt wieder im Kasten. Mannomann. Das hätte mein Ego auch nicht verkraftet, Geld zu verlieren an der Börse, und das als Aurakel. Was war das für ein ungewohntes, hässliches Gefühl. Aber jetzt ist es geheilt. :-)
3/11/2013 9:58 AM ET
CombiMatrix Corp. (CBMX: Quote) has been rising steadily since the open of trade Monday. The stock is now up 0.82 at $4.00.
CombiMatrix has climbed to a week and a half high and is approaching its 50-day moving average.
CombiMatrix Corp. (CBMX: Quote) has been rising steadily since the open of trade Monday. The stock is now up 0.82 at $4.00.
CombiMatrix has climbed to a week and a half high and is approaching its 50-day moving average.
Dallas, TX -- (SBWIRE) -- 03/12/2013 -- Marketbuzzreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
CombiMatrix Corporation (NASDAQ:CBMX) plunged 11.44% to $3.33 on a traded volume of 349k shares. On March 11, 2013, CombiMatrix Corporation received written from the NASDAQ Stock Market indicating that the Company is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the NASDAQ Capital Market. The Notice has no immediate effect on the listing of the Company's common stock.
CombiMatrix Corporation (NASDAQ:CBMX) plunged 11.44% to $3.33 on a traded volume of 349k shares. On March 11, 2013, CombiMatrix Corporation received written from the NASDAQ Stock Market indicating that the Company is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the NASDAQ Capital Market. The Notice has no immediate effect on the listing of the Company's common stock.
March 12, 2013 4:38 PM EDT
Get Alerts CBMX Hot Sheet
Price: $3.42 -9.04%
As a result of the previously disclosed resignation of Martin Felsenthal from the Board of Directors (the “Board”) of CombiMatrix Corporation (Nasdaq: CBMX) as of March 15, 2013, the Company will no longer be in compliance with NASDAQ Listing Rule 5605(b)(1) as of such date, which requires that a majority of the Board be comprised of independent directors. In accordance with NASDAQ Listing Rule 5605(b)(1)(A), the Company has until the Company’s next annual meeting of stockholders to regain compliance.
On March 8, 2013, Mark McGowan, the current Chairman of the Board of Directors of the Company, tendered his resignation from the Company’s Board and from the Board committees on which he served, effective as of the close of business on March 12, 2013. Mr. McGowan’s resignation is not a result of any disagreement with management. Mr. McGowan resigned from the Board as a result of demands related to other on-going business activities.
Although the Company previously disclosed the resignation of R. Judd Jessup from the Company’s Board to be effective as of March 15, 2012, Mr. Jessup has decided not to resign from the Board, and the Board appointed Mr. Jessup to serve in the position of Chairman of the Board effective as of the close of business on March 12, 2013 following Mr. McGowan’s resignation
Get Alerts CBMX Hot Sheet
Price: $3.42 -9.04%
As a result of the previously disclosed resignation of Martin Felsenthal from the Board of Directors (the “Board”) of CombiMatrix Corporation (Nasdaq: CBMX) as of March 15, 2013, the Company will no longer be in compliance with NASDAQ Listing Rule 5605(b)(1) as of such date, which requires that a majority of the Board be comprised of independent directors. In accordance with NASDAQ Listing Rule 5605(b)(1)(A), the Company has until the Company’s next annual meeting of stockholders to regain compliance.
On March 8, 2013, Mark McGowan, the current Chairman of the Board of Directors of the Company, tendered his resignation from the Company’s Board and from the Board committees on which he served, effective as of the close of business on March 12, 2013. Mr. McGowan’s resignation is not a result of any disagreement with management. Mr. McGowan resigned from the Board as a result of demands related to other on-going business activities.
Although the Company previously disclosed the resignation of R. Judd Jessup from the Company’s Board to be effective as of March 15, 2012, Mr. Jessup has decided not to resign from the Board, and the Board appointed Mr. Jessup to serve in the position of Chairman of the Board effective as of the close of business on March 12, 2013 following Mr. McGowan’s resignation
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: auf eigenen Wunsch des Users
CombiMatrix Corporation :
CombiMatrix Announces $2 Million Registered Direct Offering
03/20/2013| 09:57am US/Eastern
CombiMatrix Announces $2 Million Registered Direct Offering Agreement Executed for the Sale of Common and Convertible Preferred Stock and Warrants
IRVINE, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer, announced today that it has entered into an agreement to issue securities in a registered direct offering to an existing institutional investor that will result in gross proceeds to the Company totaling $2.0 million.
The Company entered into a definitive purchase agreement with the investor pursuant to which the Company has agreed to sell 130,000 shares of common stock at a negotiated price of $3.05 per share and approximately 1,610 units consisting of Series B convertible preferred stock and warrants. Each unit consists of one share of Series B convertible preferred stock and a warrant to purchase approximately 171 shares of common stock, at an exercise price of $3.49 per share. Each unit will be sold at a negotiated price of $1,000. In total, the Series B preferred is convertible into 528,000 shares of common stock and the warrants are exercisable for 275,000 shares of common stock.
The warrants are not exercisable for six months following their issue date and will expire on the fifth anniversary of the date the warrants become exercisable. The Series B preferred stock is convertible at $3.05 per share and accrues an annual dividend of 6 percent beginning six months after closing. The closing of the offering is expected to take place on or prior to March 22, 2013, subject to the satisfaction of customary closing conditions. The estimated net proceeds to the Company from the offering, after deducting placement agent fees and other estimated offering expenses payable by us, are expected to be approximately $1.76 million, to be used for general corporate purposes. With the net proceeds from this offering, the Company projects to have an unaudited cash and equivalents balance of approximately $3.3 million.
A shelf registration statement (File No. 333-176372) relating to the shares of common stock, preferred stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the preferred stock and exercise of the warrants) has been filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A prospectus supplement relating to the offering will be filed by the Company with the SEC. Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at http://www.sec.gov or from CombiMatrix Corporation, 300 Goddard, Suite 100, Irvine California 92618, Attention: Investor Relations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company in this offering. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
CombiMatrix Announces $2 Million Registered Direct Offering
03/20/2013| 09:57am US/Eastern
CombiMatrix Announces $2 Million Registered Direct Offering Agreement Executed for the Sale of Common and Convertible Preferred Stock and Warrants
IRVINE, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer, announced today that it has entered into an agreement to issue securities in a registered direct offering to an existing institutional investor that will result in gross proceeds to the Company totaling $2.0 million.
The Company entered into a definitive purchase agreement with the investor pursuant to which the Company has agreed to sell 130,000 shares of common stock at a negotiated price of $3.05 per share and approximately 1,610 units consisting of Series B convertible preferred stock and warrants. Each unit consists of one share of Series B convertible preferred stock and a warrant to purchase approximately 171 shares of common stock, at an exercise price of $3.49 per share. Each unit will be sold at a negotiated price of $1,000. In total, the Series B preferred is convertible into 528,000 shares of common stock and the warrants are exercisable for 275,000 shares of common stock.
The warrants are not exercisable for six months following their issue date and will expire on the fifth anniversary of the date the warrants become exercisable. The Series B preferred stock is convertible at $3.05 per share and accrues an annual dividend of 6 percent beginning six months after closing. The closing of the offering is expected to take place on or prior to March 22, 2013, subject to the satisfaction of customary closing conditions. The estimated net proceeds to the Company from the offering, after deducting placement agent fees and other estimated offering expenses payable by us, are expected to be approximately $1.76 million, to be used for general corporate purposes. With the net proceeds from this offering, the Company projects to have an unaudited cash and equivalents balance of approximately $3.3 million.
A shelf registration statement (File No. 333-176372) relating to the shares of common stock, preferred stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the preferred stock and exercise of the warrants) has been filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A prospectus supplement relating to the offering will be filed by the Company with the SEC. Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at http://www.sec.gov or from CombiMatrix Corporation, 300 Goddard, Suite 100, Irvine California 92618, Attention: Investor Relations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company in this offering. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
Die Liquidität wird somit sich nicht das Thema sein. Spannend wird, ob der positive Trend bei den verkauften CMA-Tests sich weiter fortsetzt.
Wenn der Zuwachs im nächsten Q-Bericht wieder 2stellig ist und der Cash Burn noch weiter abgebremst wird, dann springt Combimatrix wieder (wie unlängst) über 10$. Und die absturzartigen Kurs-Rücksetzer werden dann vielleicht endgültig der Vergangenheit angehören.
Wenn der Zuwachs im nächsten Q-Bericht wieder 2stellig ist und der Cash Burn noch weiter abgebremst wird, dann springt Combimatrix wieder (wie unlängst) über 10$. Und die absturzartigen Kurs-Rücksetzer werden dann vielleicht endgültig der Vergangenheit angehören.
Wie von mir vorausgesehen, schiesst der Kurs wieder nach oben. Mit der Meldung neuer Rekord-Verkaufszahlen war zu rechnen. Der Strategiewechsel liegt ja gerade mal 2 Quartale zurück
Bin gespannt, ob der Kurs nochmal in alte Gefilde zurückfällt. Wahrscheinlich geht's ab jetzt nur noch tendenziell nach oben. Die Rücksetzer werden sicher nicht mehr so dramatisch ausfallen. Die Firma ist jetzt grundsätzlich auf gutem Kurs.
Hoffe, ich komme nochmal unter 3 EUR rein.
Bin gespannt, ob der Kurs nochmal in alte Gefilde zurückfällt. Wahrscheinlich geht's ab jetzt nur noch tendenziell nach oben. Die Rücksetzer werden sicher nicht mehr so dramatisch ausfallen. Die Firma ist jetzt grundsätzlich auf gutem Kurs.
Hoffe, ich komme nochmal unter 3 EUR rein.
CombiMatrix (CBMX) Sees Record Prenatal Testing Volume in Q113
FREE Breaking News Alerts from StreetInsider.com!
April 4, 2013 6:19 AM
CombiMatrix Corporation (Nasdaq: CBMX) expects to report record volumes of prenatal testing in the first quarter ended March 31, 2013. Preliminary quarterly growth rates of 124 percent over the first quarter of 2012 were achieved for billable prenatal tests.
The continued rapid growth in prenatal testing is the result of CombiMatrix's strategic shift in mid-2012 to focus its commercial resources primarily on the prenatal molecular diagnostic testing markets, where the Company believes that chromosomal microarray analysis (CMA) is becoming the standard of care. This strategy is supported by a pair of National Institute of Health-sponsored studies published in the New England Journal of Medicine in late 2012, which favored CMA over traditional karyotyping for genetic prenatal diagnosis and genetic evaluation of stillbirths. Many experts believe that these publications marked the onset of a paradigm shift toward CMA. CombiMatrix is the only publicly-traded company that specializes in CMA.
The Company also announced that it was expanding its technology offerings to continue to capture market share and serve the expanding volumes. By recently incorporating Single Nucleotide Polymorphisms (SNPs) in its array testing, the Company has significantly expanded its ability for studying variations between whole genomes, which is crucial in providing resolution to its customers.
"We have been setting internal growth records since we refocused our commercial strategy, and now we are expanding our lab capabilities to realize our goal of being a best-of-class prenatal technology lab," said CEO Mark McDonough. "With the technologies to match any lab and the focus of our new prenatal strategy, we anticipate continued strong progress throughout 2013 and beyond."
Overall billable testing volumes at the Company, including its de-emphasized oncology segment, were also up strongly in the period, growing 25 percent in the quarter over 2012. CombiMatrix expects to report its operating results in early May, 2013 and file its quarterly report for 2013 on Form 10-Q in mid-May, 2013. The Company will issue a press release and hold an investor conference call to discuss results.
FREE Breaking News Alerts from StreetInsider.com!
April 4, 2013 6:19 AM
CombiMatrix Corporation (Nasdaq: CBMX) expects to report record volumes of prenatal testing in the first quarter ended March 31, 2013. Preliminary quarterly growth rates of 124 percent over the first quarter of 2012 were achieved for billable prenatal tests.
The continued rapid growth in prenatal testing is the result of CombiMatrix's strategic shift in mid-2012 to focus its commercial resources primarily on the prenatal molecular diagnostic testing markets, where the Company believes that chromosomal microarray analysis (CMA) is becoming the standard of care. This strategy is supported by a pair of National Institute of Health-sponsored studies published in the New England Journal of Medicine in late 2012, which favored CMA over traditional karyotyping for genetic prenatal diagnosis and genetic evaluation of stillbirths. Many experts believe that these publications marked the onset of a paradigm shift toward CMA. CombiMatrix is the only publicly-traded company that specializes in CMA.
The Company also announced that it was expanding its technology offerings to continue to capture market share and serve the expanding volumes. By recently incorporating Single Nucleotide Polymorphisms (SNPs) in its array testing, the Company has significantly expanded its ability for studying variations between whole genomes, which is crucial in providing resolution to its customers.
"We have been setting internal growth records since we refocused our commercial strategy, and now we are expanding our lab capabilities to realize our goal of being a best-of-class prenatal technology lab," said CEO Mark McDonough. "With the technologies to match any lab and the focus of our new prenatal strategy, we anticipate continued strong progress throughout 2013 and beyond."
Overall billable testing volumes at the Company, including its de-emphasized oncology segment, were also up strongly in the period, growing 25 percent in the quarter over 2012. CombiMatrix expects to report its operating results in early May, 2013 and file its quarterly report for 2013 on Form 10-Q in mid-May, 2013. The Company will issue a press release and hold an investor conference call to discuss results.
bin jetzt auch dabei zu 3,38usd..spannendes investment,pefekt zum traden..
Da hast Du nichts falsch gemacht. Die Aktie hüpft immer wieder nach oben. Nur keine Panik, wenn's mal wieder runter geht. Mein einziger Lichtblick in den letzten Monaten.
Hallo Aurakel,habe den wert schon länger beobachtet,am anfang wollte ich auch nicht rein,zu heftig die tagesschwankung..combimatrix ist eben noch ein schnäppchen laut marktkapitalisierung.die anleger momentan sehen das ganze noch ziemlich skeptisch,anderseits bei poitiven news explodiert die aktie kann aber selten gewinne halten.habe noch einen konkurenten? im depot(rosetta genomics)gegenüber combi in letzten monaten eher langweilig..
Ja, Gewinne fallen immer wieder zurück, obwohl die Fundamentals jetzt deutlich besser geworden sind. Wundert mich, dass wir wieder das alte Tief erreicht haben.
Ich denke jetzt ist Zeit zum Nachkaufen. Die Testverkäufe haben ja ein neues Hoch erreicht, dann wird auch der nächste Finanzbericht besser ausfallen. Ich wette auf einen anstehenden Ausbruch nach oben.
Ich denke jetzt ist Zeit zum Nachkaufen. Die Testverkäufe haben ja ein neues Hoch erreicht, dann wird auch der nächste Finanzbericht besser ausfallen. Ich wette auf einen anstehenden Ausbruch nach oben.
Antwort auf Beitrag Nr.: 44.457.751 von Aurakel am 18.04.13 10:13:56sehe ich auch so,die jetzigen kurse sollten bald der vergangenheit angehören..von allen meinen biotechs bin ich von combimatrix am meisten überzeugt,sie hat locker das potenzial eines vervielfachers.die chancen überwiegen gegenüber den risiken nach jetziger lage.
Jetzt köchelts mal wieder nach oben.
Bin mal gespannt auf den nächsten Quartalsbericht.
Meine Prognose: Kurs wird wieder 2-stellig, zumindest zeitweise, so wie bei den letzten guten News.
Das wären ca. 400% vom heutigen Stand aus gesehen.
Bin mal gespannt auf den nächsten Quartalsbericht.
Meine Prognose: Kurs wird wieder 2-stellig, zumindest zeitweise, so wie bei den letzten guten News.
Das wären ca. 400% vom heutigen Stand aus gesehen.
finanzkraft gestärkt,keine schlechten quaralszahlen und dann mal wieder so ein kursrückgang..börse ist oft nicht logisch..warten ist wieder angesagt..
Richtig, logisch kann ich mir diese Flaute erst mal nicht erklären.
Eigentlich haben sich die Basics jetzt deutlich entspannt.
Mal schauen, vielleicht kommt mit dem nächsten Quartalsbericht die Kaufpanik zurück, die schon ein paarmal da war in den letzten Monaten.
Eigentlich haben sich die Basics jetzt deutlich entspannt.
Mal schauen, vielleicht kommt mit dem nächsten Quartalsbericht die Kaufpanik zurück, die schon ein paarmal da war in den letzten Monaten.
heute mal wieder etwas schwung in dem sektor vorallem bei meinem 2 wert(rosetta genomics)combimatrix und rosetta weissen beide parallen nach aktienzusammenlegung was kursmässig möglich ist,natürlich gefüttert von guten unternehmensnews in wenigen tagen von 1,40usd auf 14,14usd bzw.23,43 zu steigen..habe mich schon lange von den langweiligen dax aktien getrennt und seit 5 jahren überdurschnittlich in us-biotechs investiert..ich liebe eben diese kursschwannkungen..
Nur, im Moment schwankt da bei Combimatrix gar nix mehr. So was von tote Hose. Dabei müsste es nach den Zahlen wieder nach oben gehen.
Noch ist der Turnaround nicht erreicht, aber in greifbare Nähe gerückt.
Noch ist der Turnaround nicht erreicht, aber in greifbare Nähe gerückt.
Antwort auf Beitrag Nr.: 44.781.315 von Aurakel am 04.06.13 12:52:16bei der nächsten aufwärtsbewegung fliegt diese kloaktie raus..
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 22, 2013
--------------------------------------------------------------------------------
CombiMatrix Corporation
(Exact name of registrant as specified in its charter)
Item 8.01 Other Events.
As previously reported, CombiMatrix Corporation (the “Company”) submitted to the NASDAQ Stock Market a plan for regaining compliance with the $2,500,000 minimum stockholders’ equity requirement for continued listing on the NASDAQ Capital Market under NASDAQ Capital Market Listing Rule 5550(b)(1) (the “Listing Rule”).
On May 22, 2013, the Company received a notification that NASDAQ has granted the Company an extension until August 20, 2013 to evidence compliance with the Listing Rule in its Form 10-Q for the quarter ending June 30, 2013, provided that prior to its next periodic filing, the Company must evidence such compliance by furnishing to the SEC and NASDAQ a publicly available report disclosing that the Company has satisfied the stockholders’ equity requirement for continued listing (among certain other related disclosures).
If the Company fails to evidence compliance upon filing its periodic report for the quarter ending June 30, 2013, the Company’s securities may be subject to delisting. In the event NASDAQ provides written notification that the Company’s securities will be delisted, the Company may appeal NASDAQ’s determination to a Listing Qualifications Panel.
There can be no assurance that the Company will timely satisfy the conditions imposed by NASDAQ or that the Company’s securities will remain listed on the NASDAQ Capital Market.
Washington, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 22, 2013
--------------------------------------------------------------------------------
CombiMatrix Corporation
(Exact name of registrant as specified in its charter)
Item 8.01 Other Events.
As previously reported, CombiMatrix Corporation (the “Company”) submitted to the NASDAQ Stock Market a plan for regaining compliance with the $2,500,000 minimum stockholders’ equity requirement for continued listing on the NASDAQ Capital Market under NASDAQ Capital Market Listing Rule 5550(b)(1) (the “Listing Rule”).
On May 22, 2013, the Company received a notification that NASDAQ has granted the Company an extension until August 20, 2013 to evidence compliance with the Listing Rule in its Form 10-Q for the quarter ending June 30, 2013, provided that prior to its next periodic filing, the Company must evidence such compliance by furnishing to the SEC and NASDAQ a publicly available report disclosing that the Company has satisfied the stockholders’ equity requirement for continued listing (among certain other related disclosures).
If the Company fails to evidence compliance upon filing its periodic report for the quarter ending June 30, 2013, the Company’s securities may be subject to delisting. In the event NASDAQ provides written notification that the Company’s securities will be delisted, the Company may appeal NASDAQ’s determination to a Listing Qualifications Panel.
There can be no assurance that the Company will timely satisfy the conditions imposed by NASDAQ or that the Company’s securities will remain listed on the NASDAQ Capital Market.
CombiMatrix Corporation : Six Months After Publication of Key Studies, CombiMatrix Sees Growth in Prenatal Testing Adoption
06/18/2013| 06:12am US/Eastern
Six Months After Publication of Key Studies, CombiMatrix Sees Growth in Prenatal Testing Adoption Growth Driven by Data Published in New England Journal of Medicine Showing Value of Chromosomal Microarray Analysis
IRVINE, Calif., June 18, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its volumes of prenatal testing have shown a significant uptick since data from two National Institutes of Health (NIH) studies showed the value of chromosomal microarray analysis (CMA).
The larger study (published in conjunction with the National Institute of Child Health and Human Development [NICHD]), which had over 4,400 patients enrolled, was published in the New England Journal of Medicine (NEMJ) in December 2012 and presented at the annual meeting of the Society for Maternal-Fetal Medicine in February, concluded that CMA identified additional clinically significant genetic abnormalities compared to traditional karyotyping when testing prenatal samples. CombiMatrix is the only publicly-traded company that specializes in CMA.
"The NICHD study clearly demonstrated the superiority of microarrays over traditional karyotyping," said Jim Goldberg, MD of San Francisco Perinatal Associates. "Due to the strength of the data in that study, we now counsel patients on the availability of microarray testing and offer this option to them as a first tier test." Dr. Goldberg reiterated, "The clinical utility of microarrays are their ability to detect chromosomal copy number abnormalities that are missed by traditional karyotyping. The accuracy of microarray, coupled with the test's fast turn-around-time, helps reduce patients' anxiety by providing comprehensive results as we move toward this new standard of care."
Some clinicians have been slow to adopt microarray testing because of concerns about variants of uncertain significance (VOUS). Dr. Goldberg emphasizes, "These types of findings are a routine part of prenatal diagnosis as a whole. Microarray testing identifies clinically significant chromosomal abnormalities that have gone undetected by karyotyping. As we learn more about these undetected chromosomal copy number changes, clinicians will become more comfortable explaining their significance to patients."
At CombiMatrix, volumes of testing for both miscarriage management and prenatal genetic testing have grown rapidly, as previously reported in the Company's first quarter 2013 earnings release.
"We believe that the very clear data published in the NEJM on both stillbirths and on invasive procedures highlight the value of CMA and is driving the uptick in our prenatal testing volumes," CombiMatrix President and CEO Mark McDonough said. "The data has generated momentum that tells us, first, we made the correct decision when we decided to make a strategic shift to focus on the developmental markets where CMA is becoming the standard of care. But second, it also shows that we continue to take market share from our competitors. We are excited and well positioned to help drive the conversion from karyotyping to microarrays over the next several quarters."
06/18/2013| 06:12am US/Eastern
Six Months After Publication of Key Studies, CombiMatrix Sees Growth in Prenatal Testing Adoption Growth Driven by Data Published in New England Journal of Medicine Showing Value of Chromosomal Microarray Analysis
IRVINE, Calif., June 18, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its volumes of prenatal testing have shown a significant uptick since data from two National Institutes of Health (NIH) studies showed the value of chromosomal microarray analysis (CMA).
The larger study (published in conjunction with the National Institute of Child Health and Human Development [NICHD]), which had over 4,400 patients enrolled, was published in the New England Journal of Medicine (NEMJ) in December 2012 and presented at the annual meeting of the Society for Maternal-Fetal Medicine in February, concluded that CMA identified additional clinically significant genetic abnormalities compared to traditional karyotyping when testing prenatal samples. CombiMatrix is the only publicly-traded company that specializes in CMA.
"The NICHD study clearly demonstrated the superiority of microarrays over traditional karyotyping," said Jim Goldberg, MD of San Francisco Perinatal Associates. "Due to the strength of the data in that study, we now counsel patients on the availability of microarray testing and offer this option to them as a first tier test." Dr. Goldberg reiterated, "The clinical utility of microarrays are their ability to detect chromosomal copy number abnormalities that are missed by traditional karyotyping. The accuracy of microarray, coupled with the test's fast turn-around-time, helps reduce patients' anxiety by providing comprehensive results as we move toward this new standard of care."
Some clinicians have been slow to adopt microarray testing because of concerns about variants of uncertain significance (VOUS). Dr. Goldberg emphasizes, "These types of findings are a routine part of prenatal diagnosis as a whole. Microarray testing identifies clinically significant chromosomal abnormalities that have gone undetected by karyotyping. As we learn more about these undetected chromosomal copy number changes, clinicians will become more comfortable explaining their significance to patients."
At CombiMatrix, volumes of testing for both miscarriage management and prenatal genetic testing have grown rapidly, as previously reported in the Company's first quarter 2013 earnings release.
"We believe that the very clear data published in the NEJM on both stillbirths and on invasive procedures highlight the value of CMA and is driving the uptick in our prenatal testing volumes," CombiMatrix President and CEO Mark McDonough said. "The data has generated momentum that tells us, first, we made the correct decision when we decided to make a strategic shift to focus on the developmental markets where CMA is becoming the standard of care. But second, it also shows that we continue to take market share from our competitors. We are excited and well positioned to help drive the conversion from karyotyping to microarrays over the next several quarters."
Ich wäre mich da nicht ganz so sicher, ob das eine Kloaktie ist.
Antwort auf Beitrag Nr.: 44.870.893 von Aurakel am 18.06.13 16:31:18vor ein paar monaten wäre die aktie bei so einer nachricht mindestens um 50% gestiegen.shorties und altaktionäre die ewig im minus waren nützen nunmal jede aufwärtsbewegung um auszusteigen..jetzt kämpft combimatrix gegen ein drohendes delisting an der nasdaq,belastet schwer den kurs.war am anfang schon überzeugt von diesem unternehmen,aber der markt spricht ne andere sprache..wünsche trotzdem allen investierten viel erfolg..
Antwort auf Beitrag Nr.: 44.871.393 von androlyt am 18.06.13 17:31:35bis jetzt an erbärmlichkeit nicht zu überbieten vom kursverlauf,trendwende nicht in sicht..gibts hier noch ein happy end???
NEWS
CombiMatrix Granted Conditional Approval From New York State Department of Health to Market Prenatal Miscarriage Analysis Test
http://finance.yahoo.com/news/combimatrix-granted-conditiona…
CombiMatrix Granted Conditional Approval From New York State Department of Health to Market Prenatal Miscarriage Analysis Test
http://finance.yahoo.com/news/combimatrix-granted-conditiona…
Gut, dass ich am Tiefstand nachgekauft habe, leider nur zu knauserig. Die langen Frustphasen machen einen paranoid, aber andererseits sind das die besten Aktien, wenn der Kurs am Boden ist und ewig keine News kommen (und notabene mit realistischer Turnaround-Chancen).
Hey franzisca, bist Du auch investiert? Rechtzeitig eingestiegen?
Hey franzisca, bist Du auch investiert? Rechtzeitig eingestiegen?
Wahnsinn, diesmal ist die Rakete richtig steil!
Ich glaube, der Sinkflug beginnt diesmal etwas später als die letzten Male. Jetzt kommt echte Hoffnung auf einen Turnaround auf.
Ich glaube, der Sinkflug beginnt diesmal etwas später als die letzten Male. Jetzt kommt echte Hoffnung auf einen Turnaround auf.
Zitat von Aurakel: Gut, dass ich am Tiefstand nachgekauft habe, leider nur zu knauserig. Die langen Frustphasen machen einen paranoid, aber andererseits sind das die besten Aktien, wenn der Kurs am Boden ist und ewig keine News kommen (und notabene mit realistischer Turnaround-Chancen).
Hey franzisca, bist Du auch investiert? Rechtzeitig eingestiegen?
Heute zu ca. 3.93$...mal schauen!
Oh je, etwas hoch zugegriffen.
Combimatrix ist wie ein Segelflieger, der ab und zu von einem Auftriebswind hochgejagt wird, und dann gleich wieder in den Sinkflug übergeht. Braucht gute Nerven. Ich gehe davon aus, dass der nächste Q-Bericht die Aktie wieder nach oben hebt.
Ich bin beim ersten Mal bei 6,50 EUR eingestiegen, nachdem die Aktie einen Peak von ca. 8 EUR hatte. War ein schöner Reinfall. Habe dann bei 3,50 EUR nachgekauft und bin später aus Panik dann bei 2,50 EUR zu 75% ausgestiegen, zwei Tage bevor der Kurs wieder explodiert ist.
Später bin ich bei 2,10 EUR mit einem etwas grösseren Betrag wieder eingestiegen und habe auf einen Kursausbruch gewartet. Das ist dann auch irgendwann eingetreten, und meine Verluste waren fast vollständig neutralisiert.
Jetzt bin ich natürlich im Plus, weil bei 2,10 EUR erneut eingestiegen. Verkaufen werde ich diesmal erst bei einem Kurs von über 5 oder 6 EUR. Alles andere wäre öde.
Ich bin sicher die Aktie kommt irgendwann sogar wieder in den 2- stelligen Bereich zurück.
Nach dem letzten Quartalsbericht mache ich mir um die Zukunftsaussichten von Combimatrix keine Sorgen mehr.
Combimatrix ist wie ein Segelflieger, der ab und zu von einem Auftriebswind hochgejagt wird, und dann gleich wieder in den Sinkflug übergeht. Braucht gute Nerven. Ich gehe davon aus, dass der nächste Q-Bericht die Aktie wieder nach oben hebt.
Ich bin beim ersten Mal bei 6,50 EUR eingestiegen, nachdem die Aktie einen Peak von ca. 8 EUR hatte. War ein schöner Reinfall. Habe dann bei 3,50 EUR nachgekauft und bin später aus Panik dann bei 2,50 EUR zu 75% ausgestiegen, zwei Tage bevor der Kurs wieder explodiert ist.
Später bin ich bei 2,10 EUR mit einem etwas grösseren Betrag wieder eingestiegen und habe auf einen Kursausbruch gewartet. Das ist dann auch irgendwann eingetreten, und meine Verluste waren fast vollständig neutralisiert.
Jetzt bin ich natürlich im Plus, weil bei 2,10 EUR erneut eingestiegen. Verkaufen werde ich diesmal erst bei einem Kurs von über 5 oder 6 EUR. Alles andere wäre öde.
Ich bin sicher die Aktie kommt irgendwann sogar wieder in den 2- stelligen Bereich zurück.
Nach dem letzten Quartalsbericht mache ich mir um die Zukunftsaussichten von Combimatrix keine Sorgen mehr.
Meldung von heute:
CombiMatrix Corporation (NASDAQ:CBMX) shares rallied 9.77 percent to $3.37 in pre-market trading after the molecular diagnostics company announced that it has entered into a contractual agreement with the health insurer, Blue Shield of California (BSCA), for coverage of its diagnostic laboratory services.
CombiMatrix Corporation (NASDAQ:CBMX) shares rallied 9.77 percent to $3.37 in pre-market trading after the molecular diagnostics company announced that it has entered into a contractual agreement with the health insurer, Blue Shield of California (BSCA), for coverage of its diagnostic laboratory services.
CombiMatrix Corporation : Reports Record Microarray Volumes for 2013 Second Quarter
08/07/2013 | 06:19am US/Eastern
CombiMatrix Corporation Reports Record Microarray Volumes for 2013 Second Quarter Prenatal Microarray Testing Volumes Grew 156% in Second Quarter; Record Cash Reimbursement; Company Expects to Regain Compliance With Nasdaq Stockholders' Equity Requirement
IRVINE, Calif., Aug. 7, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, reported today that total revenues for the second quarter and first six months of 2013 increased to $1.5 million and $3.1 million, respectively, up 15 percent and 21 percent from the second quarter and first six months of 2012, respectively. Revenues from the Company's core prenatal microarray testing markets grew by 152 percent in the second quarter of 2013 over the corresponding period in 2012, and by 159 percent year-over-year for the first six months. Prenatal microarray volumes grew by 156 percent and 171 percent in the same periods, respectively. The Company performed a total of 1,485 billable diagnostic tests for 125 customers in the second quarter of 2013, compared to 1,459 tests for 116 customers in the second quarter of 2012.
Last year, the Company announced that it would direct resources to build on its advantageous position and success in the prenatal and pediatric markets, while in oncology, it would focus almost exclusively on laboratory partnerships and de-emphasize direct oncology efforts. In addition, the Company has announced that technology advancements and the continued acceptance of microarray testing as an emerging standard would allow the Company to eliminate focus on older testing technologies to focus on microarray testing. Prenatal microarray testing revenues in the second quarter and first half of 2013 were $836,000 and $1.7 million, respectively, as compared to $331,000 and $645,000 in the 2012 periods.
CombiMatrix President and Chief Executive Officer Mark McDonough said, "We believe the quality of our testing platform and the service commitment of our organization are making it possible to succeed on multiple commercial fronts. Growth in our microarray volumes, positive coverage decisions at multiple third-party payors and the recently announced partnership with Sequenom provides evidence of that progress. In addition, we are driving the fastest growth in the most important and highest margin segment of our business - prenatal microarray testing."
"We intend to become the premier independent laboratory focusing on delivering microarray technologies," continued McDonough. "As we continue to secure partners in the marketplace that recognize the value and flexibility we provide in offering microarray services, we will also continue to build out our commercial team to take advantage of broadening geographies and the dynamic caused by all of the recent positive clinical trial data supporting microarray testing."
Total operating expenses were $3.0 million and $6.2 million for the second quarter and first six months of 2013, representing reductions of 9% and 10% from the comparable prior periods' total operating expenses of $3.3 million and $7.0 million, respectively. The reductions were primarily due to the Company's cost-cutting activities and organizational shift in mid-2012 to focus resources more fully on its core prenatal markets. CombiMatrix CFO Scott Burell said, "We have successfully controlled costs and reduced our need for cash in recent quarters. That discipline, combined with record cash reimbursement levels, the recent financing activities and common stock warrant exercises, have provided us with the highest cash balance we have had in more than 6 quarters."
Net loss was $(121,000), or $(0.03) per basic and diluted share, in the second quarter of 2013, compared to $(2.0 million), or $(1.90) per basic and diluted share, in the second quarter of 2012. Net loss was $(169,000), or $(0.06) per basic and diluted share, in the first six months of 2013, compared to $(4.4 million), or $(4.11) per basic and diluted share, in the first six months of 2012. The decrease in net loss for all periods presented was partially due to higher revenues and lower operating expenses previously discussed, but was primarily driven by non-cash, warrant derivative gains of $1.4 million and $3.3 million for the three and six months ended June 30, 2013, respectively. Under generally accepted accounting principles, warrants that were issued as part of the Company's Series A convertible preferred stock financing in the fourth quarter of 2012 are classified as derivative liabilities at fair value, with changes to fair value recognized as non-operating gains or charges in the consolidated statements of operations at each balance sheet date. Primarily as a result of certain warrant exercises during the first and second quarters of 2013, the value of the derivative warrant liabilities has decreased by a combined $3.3 million since December 31, 2012, resulting in corresponding gains to the 2013 consolidated statements of operations.
Net loss attributable to common shareholders for the three and six months ended June 30, 2013 was $(1.3 million), or $(0.37) per basic and diluted share, and $(2.1 million), or $(0.69) per basic and diluted share, respectively. Net loss attributable to common shareholders includes deemed dividends from the issuance of Series B and C convertible preferred stock of $417,000 and $1.2 million, respectively, in the first six months of 2013.
Cash and cash equivalents totaled $5.7 million as of June 30, 2013 compared to $2.4 million as of December 31, 2012. Cash used in operating activities was $(1.2 million), $(2.8 million), $(1.5 million) and $(3.1 million) for the three and six months ended June 30, 2013 and 2012, respectively, and is lower for all periods presented due to higher revenues and cost-containment efforts discussed above. The Company achieved the highest quarterly cash reimbursements in its history of $1.5 million in the 2013 second quarter, despite industry-wide shifts in reimbursement codes.
As previously reported, the Company completed a Series C convertible preferred stock financing in two tranches during the 2013 second quarter, which resulted in gross proceeds of $2.4 million. In addition, proceeds from the exercise of certain common stock warrants provided an additional $1.4 million of cash proceeds during the 2013 second quarter. Combined with first quarter financing activities, the Company has received cash proceeds from Series B and C financings and warrant exercises of $6.4 million, net of offering-related costs paid through June 30, 2013. Management believes that it now has sufficient cash resources to last into the third quarter of 2014. In addition, by achieving $5.7 million of stockholders' equity as of June 30, 2013, the Company believes it satisfies the Nasdaq listing requirement for minimum stockholders' equity and expects to regain compliance with this listing requirement after filing its Quarterly Report on Form 10-Q with the Securities and Exchange Commission. There can be no assurance, however, that the Company will be able to maintain compliance with such listing requirement in the future. On July 22, 2013, as a result of the appointment of Robert Hoffman to the Company's Board of Directors, Nasdaq notified the Company that it had regained compliance with the requirement to have a majority of independent directors.
08/07/2013 | 06:19am US/Eastern
CombiMatrix Corporation Reports Record Microarray Volumes for 2013 Second Quarter Prenatal Microarray Testing Volumes Grew 156% in Second Quarter; Record Cash Reimbursement; Company Expects to Regain Compliance With Nasdaq Stockholders' Equity Requirement
IRVINE, Calif., Aug. 7, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, reported today that total revenues for the second quarter and first six months of 2013 increased to $1.5 million and $3.1 million, respectively, up 15 percent and 21 percent from the second quarter and first six months of 2012, respectively. Revenues from the Company's core prenatal microarray testing markets grew by 152 percent in the second quarter of 2013 over the corresponding period in 2012, and by 159 percent year-over-year for the first six months. Prenatal microarray volumes grew by 156 percent and 171 percent in the same periods, respectively. The Company performed a total of 1,485 billable diagnostic tests for 125 customers in the second quarter of 2013, compared to 1,459 tests for 116 customers in the second quarter of 2012.
Last year, the Company announced that it would direct resources to build on its advantageous position and success in the prenatal and pediatric markets, while in oncology, it would focus almost exclusively on laboratory partnerships and de-emphasize direct oncology efforts. In addition, the Company has announced that technology advancements and the continued acceptance of microarray testing as an emerging standard would allow the Company to eliminate focus on older testing technologies to focus on microarray testing. Prenatal microarray testing revenues in the second quarter and first half of 2013 were $836,000 and $1.7 million, respectively, as compared to $331,000 and $645,000 in the 2012 periods.
CombiMatrix President and Chief Executive Officer Mark McDonough said, "We believe the quality of our testing platform and the service commitment of our organization are making it possible to succeed on multiple commercial fronts. Growth in our microarray volumes, positive coverage decisions at multiple third-party payors and the recently announced partnership with Sequenom provides evidence of that progress. In addition, we are driving the fastest growth in the most important and highest margin segment of our business - prenatal microarray testing."
"We intend to become the premier independent laboratory focusing on delivering microarray technologies," continued McDonough. "As we continue to secure partners in the marketplace that recognize the value and flexibility we provide in offering microarray services, we will also continue to build out our commercial team to take advantage of broadening geographies and the dynamic caused by all of the recent positive clinical trial data supporting microarray testing."
Total operating expenses were $3.0 million and $6.2 million for the second quarter and first six months of 2013, representing reductions of 9% and 10% from the comparable prior periods' total operating expenses of $3.3 million and $7.0 million, respectively. The reductions were primarily due to the Company's cost-cutting activities and organizational shift in mid-2012 to focus resources more fully on its core prenatal markets. CombiMatrix CFO Scott Burell said, "We have successfully controlled costs and reduced our need for cash in recent quarters. That discipline, combined with record cash reimbursement levels, the recent financing activities and common stock warrant exercises, have provided us with the highest cash balance we have had in more than 6 quarters."
Net loss was $(121,000), or $(0.03) per basic and diluted share, in the second quarter of 2013, compared to $(2.0 million), or $(1.90) per basic and diluted share, in the second quarter of 2012. Net loss was $(169,000), or $(0.06) per basic and diluted share, in the first six months of 2013, compared to $(4.4 million), or $(4.11) per basic and diluted share, in the first six months of 2012. The decrease in net loss for all periods presented was partially due to higher revenues and lower operating expenses previously discussed, but was primarily driven by non-cash, warrant derivative gains of $1.4 million and $3.3 million for the three and six months ended June 30, 2013, respectively. Under generally accepted accounting principles, warrants that were issued as part of the Company's Series A convertible preferred stock financing in the fourth quarter of 2012 are classified as derivative liabilities at fair value, with changes to fair value recognized as non-operating gains or charges in the consolidated statements of operations at each balance sheet date. Primarily as a result of certain warrant exercises during the first and second quarters of 2013, the value of the derivative warrant liabilities has decreased by a combined $3.3 million since December 31, 2012, resulting in corresponding gains to the 2013 consolidated statements of operations.
Net loss attributable to common shareholders for the three and six months ended June 30, 2013 was $(1.3 million), or $(0.37) per basic and diluted share, and $(2.1 million), or $(0.69) per basic and diluted share, respectively. Net loss attributable to common shareholders includes deemed dividends from the issuance of Series B and C convertible preferred stock of $417,000 and $1.2 million, respectively, in the first six months of 2013.
Cash and cash equivalents totaled $5.7 million as of June 30, 2013 compared to $2.4 million as of December 31, 2012. Cash used in operating activities was $(1.2 million), $(2.8 million), $(1.5 million) and $(3.1 million) for the three and six months ended June 30, 2013 and 2012, respectively, and is lower for all periods presented due to higher revenues and cost-containment efforts discussed above. The Company achieved the highest quarterly cash reimbursements in its history of $1.5 million in the 2013 second quarter, despite industry-wide shifts in reimbursement codes.
As previously reported, the Company completed a Series C convertible preferred stock financing in two tranches during the 2013 second quarter, which resulted in gross proceeds of $2.4 million. In addition, proceeds from the exercise of certain common stock warrants provided an additional $1.4 million of cash proceeds during the 2013 second quarter. Combined with first quarter financing activities, the Company has received cash proceeds from Series B and C financings and warrant exercises of $6.4 million, net of offering-related costs paid through June 30, 2013. Management believes that it now has sufficient cash resources to last into the third quarter of 2014. In addition, by achieving $5.7 million of stockholders' equity as of June 30, 2013, the Company believes it satisfies the Nasdaq listing requirement for minimum stockholders' equity and expects to regain compliance with this listing requirement after filing its Quarterly Report on Form 10-Q with the Securities and Exchange Commission. There can be no assurance, however, that the Company will be able to maintain compliance with such listing requirement in the future. On July 22, 2013, as a result of the appointment of Robert Hoffman to the Company's Board of Directors, Nasdaq notified the Company that it had regained compliance with the requirement to have a majority of independent directors.
CombiMatrix Regains Compliance With Nasdaq Min. Stockholders' Equity Requirement
WASHINGTON (dpa-AFX) - CombiMatrix Corp.(CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, announced that in a letter dated August 20, 2013, from the Director of Listing Qualifications of The Nasdaq Stock Market LLC, the company was informed that it has regained compliance with Listing Rule 5550(b)(1), which requires a minimum of $2.5 million stockholders' equity for The Nasdaq Capital Market.
The letter from Nasdaq said that based on the company's Form 10-Q for the period ended June 30, 2013, which evidenced stockholders' equity of $5.7 million, the Nasdaq Staff has determined that CombiMatrix complies with the Rule and 'the matter is now closed.'
Copyright RTT News/dpa-AFX
© 2013 AFX News
WASHINGTON (dpa-AFX) - CombiMatrix Corp.(CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, announced that in a letter dated August 20, 2013, from the Director of Listing Qualifications of The Nasdaq Stock Market LLC, the company was informed that it has regained compliance with Listing Rule 5550(b)(1), which requires a minimum of $2.5 million stockholders' equity for The Nasdaq Capital Market.
The letter from Nasdaq said that based on the company's Form 10-Q for the period ended June 30, 2013, which evidenced stockholders' equity of $5.7 million, the Nasdaq Staff has determined that CombiMatrix complies with the Rule and 'the matter is now closed.'
Copyright RTT News/dpa-AFX
© 2013 AFX News
Relatively Low Price to Book Ratio Detected in Shares of CombiMatrix in the Life Sciences Tools & Services Industry (CBMX, HBIO, BIO, QGEN, AFFX)
Written on Thu, 10/17/2013 - 6:42am
By Amy Schwartz
Below are the three companies in the Life Sciences Tools & Services industry with the lowest price to book ratios. Often companies with the lowest ratio present the greatest value to investors.
CombiMatrix ranks lowest with a a price to book ratio of 0.76. Following is Harvard Bioscience with a a price to book ratio of 1.53. Bio-Rad Laboratories ranks third lowest with a a price to book ratio of 1.67.
QIAGEN follows with a a price to book ratio of 1.89, and Affymetrix rounds out the bottom five with a a price to book ratio of 1.90.
SmarTrend recommended that subscribers consider buying shares of Affymetrix on August 6th, 2013 as our technology indicated a new Uptrend was in progress when shares hit $4.81. Since that recommendation, shares of Affymetrix have risen 42.2%. We continue to monitor Affymetrix for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
Written on Thu, 10/17/2013 - 6:42am
By Amy Schwartz
Below are the three companies in the Life Sciences Tools & Services industry with the lowest price to book ratios. Often companies with the lowest ratio present the greatest value to investors.
CombiMatrix ranks lowest with a a price to book ratio of 0.76. Following is Harvard Bioscience with a a price to book ratio of 1.53. Bio-Rad Laboratories ranks third lowest with a a price to book ratio of 1.67.
QIAGEN follows with a a price to book ratio of 1.89, and Affymetrix rounds out the bottom five with a a price to book ratio of 1.90.
SmarTrend recommended that subscribers consider buying shares of Affymetrix on August 6th, 2013 as our technology indicated a new Uptrend was in progress when shares hit $4.81. Since that recommendation, shares of Affymetrix have risen 42.2%. We continue to monitor Affymetrix for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
so unrecht hatte ich nicht vor einiger zeit(kloaktie)...
Ob es wirklich eine Kloaktie ist, werden wir ja noch sehen. Manchmal sind die besten Aktien jene, die extrem frustrierend verlaufend und irgendwann plötzlich neu erwachen.
Da ich bei 2 EUR gekauft habe, bin ich zur Zeit wieder im Plus.
Aber es stimmt, es nervt, dass es nach einem starken Anstieg jedesmal binnen weniger Stunden wieder runterschmilzt. Da lädt wohl jemand bei jeder positiven Meldung ab. Sonst wären wir schon längst wieder im Himmel.
Die Zukunftsaussichten sind jedenfalls sehr vielversprechend, siehe nachfolgende Meldung:
Da ich bei 2 EUR gekauft habe, bin ich zur Zeit wieder im Plus.
Aber es stimmt, es nervt, dass es nach einem starken Anstieg jedesmal binnen weniger Stunden wieder runterschmilzt. Da lädt wohl jemand bei jeder positiven Meldung ab. Sonst wären wir schon längst wieder im Himmel.
Die Zukunftsaussichten sind jedenfalls sehr vielversprechend, siehe nachfolgende Meldung:
CombiMatrix (CBMX) Stock Gains Following ACOG Recommendation
December 5, 2013 7:38 AM EST
Get Alerts CBMX Hot Sheet
Price: $3.08 +4.41%
CombiMatrix Corporation (Nasdaq: CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that the American College of Obstetricians and Gynecologists (ACOG) has issued new guidelines indicating that chromosomal microarray analysis (CMA) is now recommended as the first-line genetic test in pregnancies showing fetal abnormalities on an ultrasound screen.
The ACOG guidelines also indicate that microarray testing is recommended as the preferred genetic test to help identify the cause of death in stillbirths and intrauterine fetal demise when further cytogenetic analysis is desired because of its increased likelihood of obtaining results and improved detection of causative abnormalities.
CMA is a DNA-based method of prenatal genetic testing. Like the conventional prenatal genetic test known as karyotyping, CMA can identify major chromosomal defects such as Down syndrome. But CMA can also find many other genetic defects that are too small to be detected by karyotyping. Both CMA and karyotyping require testing of fetal tissue obtained with chorionic villus sampling (CVS) or amniocentesis.
"We believe this new guidance from ACOG recommending CMA as the first-line test when an ultrasound reveals one or more major fetal abnormalities is a significant milestone in the evolution of genetic testing for fetal abnormalities, but one that we had expected based on the clinical data from recently published studies," said Mark McDonough, President and CEO. "Due to the support of ACOG and its opinion leaders, we believe clinicians are now more likely to counsel patients on the availability of microarray testing and offer this option to them as a first-line test. We believe ACOG's recognition of microarray testing's increased likelihood of obtaining results and improved detection of causative abnormalities in stillbirths and intrauterine fetal demise also is an important milestone in those areas of care."
December 5, 2013 7:38 AM EST
Get Alerts CBMX Hot Sheet
Price: $3.08 +4.41%
CombiMatrix Corporation (Nasdaq: CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that the American College of Obstetricians and Gynecologists (ACOG) has issued new guidelines indicating that chromosomal microarray analysis (CMA) is now recommended as the first-line genetic test in pregnancies showing fetal abnormalities on an ultrasound screen.
The ACOG guidelines also indicate that microarray testing is recommended as the preferred genetic test to help identify the cause of death in stillbirths and intrauterine fetal demise when further cytogenetic analysis is desired because of its increased likelihood of obtaining results and improved detection of causative abnormalities.
CMA is a DNA-based method of prenatal genetic testing. Like the conventional prenatal genetic test known as karyotyping, CMA can identify major chromosomal defects such as Down syndrome. But CMA can also find many other genetic defects that are too small to be detected by karyotyping. Both CMA and karyotyping require testing of fetal tissue obtained with chorionic villus sampling (CVS) or amniocentesis.
"We believe this new guidance from ACOG recommending CMA as the first-line test when an ultrasound reveals one or more major fetal abnormalities is a significant milestone in the evolution of genetic testing for fetal abnormalities, but one that we had expected based on the clinical data from recently published studies," said Mark McDonough, President and CEO. "Due to the support of ACOG and its opinion leaders, we believe clinicians are now more likely to counsel patients on the availability of microarray testing and offer this option to them as a first-line test. We believe ACOG's recognition of microarray testing's increased likelihood of obtaining results and improved detection of causative abnormalities in stillbirths and intrauterine fetal demise also is an important milestone in those areas of care."
News - Artikel von Seeking-Alpha:
CombiMatrix: A Turnaround Story For 2014
Jan. 22, 2014 9:44 AM ET | About: CBMX
Disclosure: I am long CBMX, . (More...)
Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
As a small cap biotech investor it is difficult to locate under the radar companies that haven't exploded in recent months. 2013 was an incredible year for most biotech investors as the IBB and XBI finished the year up 60.33% and 42.7% respectively. As we going into 2014 it is becoming increasingly more difficult to find the next big run up play, but one company, CombiMatrix Corporation (CBMX), has caught our eye and could provide significant returns in 2014.
This past year, 2013, has been an incredible year for CombiMatrix. CombiMatrix is a molecular diagnostic company specializing in DNA-based testing services for developmental disorders and cancer diagnostics. The company specializes in Chromosomal Microarray Analysis (CMA), which is a technique used to identify chromosomal abnormalities, including submicroscopic abnormalities that are too small to be detected by conventional Karyotyping. Until recently, the broad application of this technology was limited by a lack of large population based studies.
In December of 2012, two studies conducted by the National Institutes of Health (NIH) were published in the New England Journal of Medicine. These studies were the largest head-to-head studies comparing CMA to traditional Karyotyping for genetic prenatal diagnosis and genetic evaluation of stillbirth. Both studies favored CMA, stating that it identified additional, clinically significant genetic abnormalities not identified through traditional Karyotyping.
This was just the spark that CombiMatrix needed as the company has experienced incredible growth since.
2013 Growth Highlights
In February of 2013,CombiMatrix (the company) introduced their new CEO, Mark McDonough. As a former VP of sales at LabCorp of America, McDonough brings with him a strong background in diagnostic sales and business development. In the timesince McDonough took over the CEO position, the company has signed numerous contracts and developed partnerships with premier healthcare providers.
page 1 / 2
|
Next »
CombiMatrix: A Turnaround Story For 2014
Jan. 22, 2014 9:44 AM ET | About: CBMX
Disclosure: I am long CBMX, . (More...)
Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
As a small cap biotech investor it is difficult to locate under the radar companies that haven't exploded in recent months. 2013 was an incredible year for most biotech investors as the IBB and XBI finished the year up 60.33% and 42.7% respectively. As we going into 2014 it is becoming increasingly more difficult to find the next big run up play, but one company, CombiMatrix Corporation (CBMX), has caught our eye and could provide significant returns in 2014.
This past year, 2013, has been an incredible year for CombiMatrix. CombiMatrix is a molecular diagnostic company specializing in DNA-based testing services for developmental disorders and cancer diagnostics. The company specializes in Chromosomal Microarray Analysis (CMA), which is a technique used to identify chromosomal abnormalities, including submicroscopic abnormalities that are too small to be detected by conventional Karyotyping. Until recently, the broad application of this technology was limited by a lack of large population based studies.
In December of 2012, two studies conducted by the National Institutes of Health (NIH) were published in the New England Journal of Medicine. These studies were the largest head-to-head studies comparing CMA to traditional Karyotyping for genetic prenatal diagnosis and genetic evaluation of stillbirth. Both studies favored CMA, stating that it identified additional, clinically significant genetic abnormalities not identified through traditional Karyotyping.
This was just the spark that CombiMatrix needed as the company has experienced incredible growth since.
2013 Growth Highlights
In February of 2013,CombiMatrix (the company) introduced their new CEO, Mark McDonough. As a former VP of sales at LabCorp of America, McDonough brings with him a strong background in diagnostic sales and business development. In the timesince McDonough took over the CEO position, the company has signed numerous contracts and developed partnerships with premier healthcare providers.
page 1 / 2
|
Next »
THE STREET
CombiMatrix Poised to Double -- or More
BY Roberto Pedone | 03/17/14 - 02:01 PM EDT
DELAFIELD, Wis. (Stockpickr) -- When I scan the small-cap biotech and health care sectors, I am always looking for a stock that has two major things going for it: a strong fundamental story and a bullish technical chart setup. Those two elements can be a powerful combination, since they can quickly bring together fundamental investors and technical traders who can push a stock substantially higher when they work in concert.
I believe I have discovered the next small-cap health care stock that has a perfect storm of those two key elements. This potentially perfect storm is still in the early stages, so this stock could very well be offering market players a very attractive entry point.
The company I see big opportunity in here is CombiMatrix (CBMX_), which is a molecular diagnostics player that operates primarily in the field of genetic analysts and molecular diagnostics. This company specializes in cytogenetic testing for prenatal diagnosis, miscarriage analysis and pediatric development disorders. The company's microarray testing addresses various common hematological malignancies, primarily chronic lymphocytic leukemia. CombiMatrix's customers are commercial insurance companies, health care institutions, government payers and individuals.
During the firm's latest earnings report, CombiMatrix said revenue for the fourth quarter and full year increased to $1.76 million and $6.37 million, respectively, or 18% and 19% growth from the comparable periods in 2012. Revenue for its core prenatal microarray testing markets grew by 22% from the third quarter of 2013 and 112% year over year. Sales volumes for prenatal microarray testing increased 74% and 126% for the fourth quarter and for the comparable period in 2012.
CombiMatrix CEO Mark McDonough said on the company's most recent conference call that he believes there is no reason why the company can't keep this kind of growth going in 2014 and beyond. McDonough pointed out that the company has been expanding its sales force and plans to hire as many as 15 new members in the near future. You can really understand why he's excited since the estimated market for their products is in excess of $350 million annually.
I believe that CombiMatrix could double or much more from its current price level of around $3.25 per share for a variety of reasons. First, CBMX is an attractive takeover target, since it has accelerated growth and a market cap of just $15 million. That market cap does not reflect the opportunity for CBMX to growth substantially as it takes share and attacks the $350 million market for its products. Second, this stock has favorable technical setup that is rapidly developing as I write this. I will touch more on that shortly. Third, this company has all the reason in the world to announce more new partnerships that will expand its markets and increase cash flow. And finally, CBMX, for whatever crazy reason, has a ton of short-sellers that are currently betting against this company. Those shorts, if wrong, have the potential to be the fuel to this rocket ship if the stock can finally sustain some gains and break out above some key overhead resistance levels.
The current short interest as a percentage of the float for CombiMatrix is ridiculously large at 24.6%. That means that out of the 4.56 million shares in the tradable float, 1.12 million shares are currently sold short by the bears. The shorts have also been increasing their bets from the last reporting period by 14.5%, or by about 140,000 shares. This is a low-float stock with a monster short interest, and it's a company with an intriguing fundamental story -- a powerful combination that can easily send shares of CBMX exploding higher on any good news or large new partnership announcements.
CombiMatrix Poised to Double -- or More
BY Roberto Pedone | 03/17/14 - 02:01 PM EDT
DELAFIELD, Wis. (Stockpickr) -- When I scan the small-cap biotech and health care sectors, I am always looking for a stock that has two major things going for it: a strong fundamental story and a bullish technical chart setup. Those two elements can be a powerful combination, since they can quickly bring together fundamental investors and technical traders who can push a stock substantially higher when they work in concert.
I believe I have discovered the next small-cap health care stock that has a perfect storm of those two key elements. This potentially perfect storm is still in the early stages, so this stock could very well be offering market players a very attractive entry point.
The company I see big opportunity in here is CombiMatrix (CBMX_), which is a molecular diagnostics player that operates primarily in the field of genetic analysts and molecular diagnostics. This company specializes in cytogenetic testing for prenatal diagnosis, miscarriage analysis and pediatric development disorders. The company's microarray testing addresses various common hematological malignancies, primarily chronic lymphocytic leukemia. CombiMatrix's customers are commercial insurance companies, health care institutions, government payers and individuals.
During the firm's latest earnings report, CombiMatrix said revenue for the fourth quarter and full year increased to $1.76 million and $6.37 million, respectively, or 18% and 19% growth from the comparable periods in 2012. Revenue for its core prenatal microarray testing markets grew by 22% from the third quarter of 2013 and 112% year over year. Sales volumes for prenatal microarray testing increased 74% and 126% for the fourth quarter and for the comparable period in 2012.
CombiMatrix CEO Mark McDonough said on the company's most recent conference call that he believes there is no reason why the company can't keep this kind of growth going in 2014 and beyond. McDonough pointed out that the company has been expanding its sales force and plans to hire as many as 15 new members in the near future. You can really understand why he's excited since the estimated market for their products is in excess of $350 million annually.
I believe that CombiMatrix could double or much more from its current price level of around $3.25 per share for a variety of reasons. First, CBMX is an attractive takeover target, since it has accelerated growth and a market cap of just $15 million. That market cap does not reflect the opportunity for CBMX to growth substantially as it takes share and attacks the $350 million market for its products. Second, this stock has favorable technical setup that is rapidly developing as I write this. I will touch more on that shortly. Third, this company has all the reason in the world to announce more new partnerships that will expand its markets and increase cash flow. And finally, CBMX, for whatever crazy reason, has a ton of short-sellers that are currently betting against this company. Those shorts, if wrong, have the potential to be the fuel to this rocket ship if the stock can finally sustain some gains and break out above some key overhead resistance levels.
The current short interest as a percentage of the float for CombiMatrix is ridiculously large at 24.6%. That means that out of the 4.56 million shares in the tradable float, 1.12 million shares are currently sold short by the bears. The shorts have also been increasing their bets from the last reporting period by 14.5%, or by about 140,000 shares. This is a low-float stock with a monster short interest, and it's a company with an intriguing fundamental story -- a powerful combination that can easily send shares of CBMX exploding higher on any good news or large new partnership announcements.
Fortsetzung (Seite 2)
[...]
If you take a look at the chart for shares of CombiMatrix, you'll see that this stock has been consolidating and trending range-bound for the last two months and change, with shares moving between $2.40 on the downside and $3.43 on the upside. Despite this sideways trading chart pattern for shares of CBMX, this stock has been making higher lows each time it has pulled back over that timeframe. That demonstrates that buyers are eager to snap up CBMX on the dips. This stock has a trading history of being faded whenever it spikes, so it's key for traders to watch for a change in that trading characteristic. I think that change could be happening right now.
Shares of CBMX are spiking sharply higher today by just over 5% with heavy upside volume. Volume so far today has already surpassed 1.6 million shares, which is well above its three-month average action of 888,225 shares. This spike is quickly pushing shares of CBMX within range of triggering a major breakout trade above some key overhead resistance levels.
Traders should look for long-biased trades in CBMX as long as it's trending above some near-term support levels at $2.80 to $2.60 a share and then once it breaks out above those key overhead resistance levels at $3.43 to $3.70 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 888,225 shares. If that breakout begins soon, then shares of CBMX should easily soar back to its next major overhead resistance levels at $4.44 to its 52-week high of $4.62 a share. If those levels get taken out with volume, then all the fun should begin for CMBX since it has little resistance until $7.64 a share.
The bottom line: CBMX has a great fundamental story with high growth rates and a strong technical chart setup. The icing on the cake is the large amount of bears that are involved in this stock. If those bears are wrong, and I think they are, then this stock is going to explode and double easily from current levels.
-- Written by Roberto Pedone in Delafield, Wis.
[...]
If you take a look at the chart for shares of CombiMatrix, you'll see that this stock has been consolidating and trending range-bound for the last two months and change, with shares moving between $2.40 on the downside and $3.43 on the upside. Despite this sideways trading chart pattern for shares of CBMX, this stock has been making higher lows each time it has pulled back over that timeframe. That demonstrates that buyers are eager to snap up CBMX on the dips. This stock has a trading history of being faded whenever it spikes, so it's key for traders to watch for a change in that trading characteristic. I think that change could be happening right now.
Shares of CBMX are spiking sharply higher today by just over 5% with heavy upside volume. Volume so far today has already surpassed 1.6 million shares, which is well above its three-month average action of 888,225 shares. This spike is quickly pushing shares of CBMX within range of triggering a major breakout trade above some key overhead resistance levels.
Traders should look for long-biased trades in CBMX as long as it's trending above some near-term support levels at $2.80 to $2.60 a share and then once it breaks out above those key overhead resistance levels at $3.43 to $3.70 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 888,225 shares. If that breakout begins soon, then shares of CBMX should easily soar back to its next major overhead resistance levels at $4.44 to its 52-week high of $4.62 a share. If those levels get taken out with volume, then all the fun should begin for CMBX since it has little resistance until $7.64 a share.
The bottom line: CBMX has a great fundamental story with high growth rates and a strong technical chart setup. The icing on the cake is the large amount of bears that are involved in this stock. If those bears are wrong, and I think they are, then this stock is going to explode and double easily from current levels.
-- Written by Roberto Pedone in Delafield, Wis.
Wäre gestern fast wieder eingestiegen, aber dann ist das Strohfeuer verpufft und ich habe meine Kauforder zurückgezogen.
Trotzdem, mit guten Quartalszahlen kanns hier jederzeit wieder eine Rakete geben. Hoffentlich finde ich rechtzeitig den Wiedereinstieg.
Trotzdem, mit guten Quartalszahlen kanns hier jederzeit wieder eine Rakete geben. Hoffentlich finde ich rechtzeitig den Wiedereinstieg.
das wars wohl mit cmbx..im nächsten jahr an der otc als pennystock..
Antwort auf Beitrag Nr.: 48.059.206 von gerdass am 16.10.14 19:22:54Gibts nen Grund für den Anstieg?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -0,12 | |
| -4,65 | |
| 0,00 | |
| -0,63 | |
| -1,02 | |
| +0,14 | |
| -1,82 | |
| -0,47 | |
| 0,00 | |
| -21,05 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 203 | ||
| 114 | ||
| 73 | ||
| 66 | ||
| 63 | ||
| 57 | ||
| 57 | ||
| 54 | ||
| 45 | ||
| 42 |
